USPTO Examiner VANNI GEORGE STEVEN - Art Unit 1672

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
17113008GENE EXPRESSION ANALYSIS TECHNIQUES USING GENE RANKINGS AND STATISTICAL MODELS FOR IDENTIFYING BIOLOGICAL SAMPLE CHARACTERISTICSDecember 2020July 2022Allow1931YesNo
17108958MACHINE LEARNING METHOD FOR PROTEIN MODELLING TO DESIGN ENGINEERED PEPTIDESDecember 2020July 2022Allow1921YesNo
17108890Protein Structure Prediction from Amino Acid Sequences Using Self-Attention Neural NetworksDecember 2020November 2023Allow3610YesNo
17001804CHEMICAL REACTION NETWORK FOR ESTIMATING CONCENTRATION OF CHEMICAL SPECIES BASED ON AN IDENTIFIED PATTERN OF OUTPUT CHEMICAL SPECIESAugust 2020May 2023Allow3322YesNo
16919154METHODS AND SYSTEMS FOR PATIENT BASELINE ESTIMATIONJuly 2020November 2023Allow4020NoNo
16946534MEASURING AND REMOVING NOISE IN STOCHASTIC SIGNALS FROM A NANOPORE DNA SEQUENCING SYSTEM DRIVEN BY AN ALTERNATING SIGNALJune 2020March 2022Allow2110NoNo
16893213Biological Deposit Labeling And Tracking Including Isotope, Rare Earth Metal Or Mitochondria TagsJune 2020April 2024Allow4610NoNo
16883833GENE EXPRESSION PROFILING FROM FFPE SAMPLESMay 2020July 2023Abandon3810NoNo
16877729BIOLOGICS ENGINEERING VIA APTAMOMIMETIC DISCOVERYMay 2020November 2023Allow4220YesNo
16854378Methods and Systems for Use in Cancer PredictionApril 2020March 2024Allow4730YesNo
16851578PERSONALIZED MEDICAL MONITORING AND NOTIFICATIONS THEREFORApril 2020January 2024Allow4531YesYes
16819972METHODS AND SYSTEMS FOR PREDICTING THE RISK OF TRANSGENE SILENCINGMarch 2020April 2024Abandon4910YesNo
16796748METHODS FOR AMPLIFICATION OF CELL-FREE DNA USING LIGATED ADAPTORS AND UNIVERSAL AND INNER TARGET-SPECIFIC PRIMERS FOR MULTIPLEXED NESTED PCRFebruary 2020January 2021Abandon1111YesNo
16728259SPATIAL ANALYTICAL MICROBIAL IMAGINGDecember 2019September 2024Abandon5701YesNo
16727879ULTRASOUND DEVICES AND SYSTEMS FOR DETERMINING CONSTITUTIVE RELATIONS AND FIBER ORIENTATION OF SOFT TISSUESDecember 2019June 2023Allow4210NoNo
16720172METHODS FOR IDENTIFYING AGENTS WITH DESIRED BIOLOGICAL ACTIVITYDecember 2019May 2024Abandon5201NoNo
16708312PREDICTING PATIENT RESPONSE TO SODIUM CHANNEL BLOCKERSDecember 2019June 2024Allow5420YesNo
16703792FEATURE IDENTIFYING METHOD AND ELECTRONIC DEVICEDecember 2019September 2023Allow4521YesNo
16659154MULTI-PARAMETER PHYSIOLOGICAL MAPPING TO A MULTI-DIMENSIONAL COLOR MODELOctober 2019October 2023Allow4811NoNo
16565773MANIPULATING DROPLET SIZESeptember 2019October 2023Allow4911YesNo
16544316Systems for Non-Invasive Assessment of Chromosome Alterations Using Changes in Subsequence MappabilityAugust 2019October 2023Allow5020YesNo
16504158SIMULATING EVOLUTION OF A TUMORJuly 2019December 2023Allow5320YesNo
16459049IDENTIFACTION OF CANCER BIOMARKERS BY ALIGNMENT OF NUCLEIC ACID SEQUENCESJuly 2019August 2023Allow5010YesNo
16456462SYSTEMS AND METHODS FOR PREDICTING THERAPY EFFICACY FROM NORMALIZED BIOMARKER SCORESJune 2019August 2023Allow5040YesNo
16443968SIMULATIONS NETWORKED ACTIVITY USING DYNAMICS- BASED CONSTRAINTS ON REUSABLE NETWORK COMPONENTJune 2019April 2023Allow4610YesNo
16390648TESTING AND REPRESENTING SUSPICION OF SEPSISApril 2019June 2022Allow3820YesNo
16383248SYSTEM ERROR COMPENSATION OF ANALYTE CONCENTRATION DETERMINATIONS BASED ON PSEUDO-REFERENCE CONCENTRATION AND SIGNAL-BASED ANCHOR PARAMETERSApril 2019October 2023Allow5411YesNo
16341438THE PRIMARY SITE OF METASTATIC CANCER IDENTIFICATION METHOD AND SYSTEM THEREOFApril 2019April 2023Abandon4801NoNo
16365048EXCLUDING VARIANT PATTERNS FROM SEQUENCES APPARATUS, METHOD, AND STORAGE MEDIUMMarch 2019August 2024Abandon6020NoNo
16355590METHODS USING CHROMATIN-RELATED NUCLEIC ACID SIGNALS FOR PERFORMING CLINICAL ACTIONSMarch 2019April 2024Allow6021YesNo
16279764SYSTEMS AND METHODS FOR STIMULATION-RELATED BIOLOGICAL CIRCUIT ELEMENT ANALYSIS AND USEFebruary 2019January 2023Allow4721YesNo
16279785SYSTEMS AND METHODS FOR STIMULATION-RELATED VOLUME ANALYSIS OF THERAPEUTIC EFFECTS AND OTHER CLINICAL INDICATIONSFebruary 2019December 2022Allow4611YesNo
16267778Quality score compression apparatus and method for improving downstream accuracyFebruary 2019May 2023Allow5120YesNo
16246420DETERMINING A NUCLEIC ACID SEQUENCE IMBALANCE USING MULTIPLE MARKERSJanuary 2019March 2023Allow5021YesNo
16232928METAGENOMICS FOR MICROBIOMESDecember 2018June 2022Allow4210YesNo
16312820COGNITIVE CELL WITH CODED CHEMICALS FOR GENERATING OUTPUTS FROM ENVIRONMENTAL INPUTS AND METHOD OF USING SAMEDecember 2018April 2023Abandon5232NoNo
16309489PERSONALISED NUTRIENT DOSING WITH ON-GOING FEEDBACK LOOPDecember 2018June 2022Allow4211YesNo
16217718Methods for Using Nucleic Acids to Store, Retrieve and Access Information Comprising a Text, Image, Video or Audio FormatDecember 2018August 2022Allow4420YesNo
16216770ANONYMIZING GENETIC DATASETS IN A DISPARATE COMPUTING ENVIRONMENTDecember 2018July 2022Allow4320YesNo
16214327TRANSCRIPTOME-WIDE DESIGN OF SELECTIVE, BIOACTIVE SMALL MOLECULES TARGETING RNADecember 2018December 2022Allow4821YesNo
16308721GRAPHICAL REPRESENTATION OF A DYNAMIC KNEE SCORE FOR A KNEE SURGERYDecember 2018September 2022Allow4510YesNo
16213677Methods And Systems For Identifying Hybrids For Use In Plant BreedingDecember 2018November 2022Allow4812NoNo
16213596Methods And Systems For Identifying Progenies For Use In Plant BreedingDecember 2018March 2023Allow5211NoNo
16202889IDENTIFYING KNOWLEDGE GAPS UTILIZING COGNITIVE NETWORK META-ANALYSISNovember 2018June 2022Allow4320YesNo
16203040COMPUTING SYSTEM FOR NORMALIZING COMPUTER-READABLE GENETIC TEST RESULTS FROM NUMEROUS DIFFERENT SOURCESNovember 2018October 2022Allow4620NoNo
16304890ASSESSING THE FUNCTIONAL ABILITY OF A PERSON TO PERFORM A TASKNovember 2018September 2022Allow4520NoNo
16199701SYSTEM AND METHOD FOR PREDICTION-MODEL-BASED DISPLAY OF DISTRIBUTIONS OF HEALTH OUTCOME INFORMATION FOR PATIENT POPULATIONS IN GEOGRAPHICAL AREASNovember 2018January 2023Allow5031YesNo
16302542A SYSTEM TO COMPARE AT LEAST ONE DNA FRAGMENT TO A REFERENCE GENOMENovember 2018February 2023Allow5111NoNo
16172351SYSTEM AND METHOD FOR ANALYZING DISEASES AND DISEASE DEVELOPMENTOctober 2018July 2024Abandon6040YesYes
16092372NUCLEOLAR DISRUPTION DETERMINATION AND SCORING OF IMAGESOctober 2018November 2023Abandon6021NoNo
16151217DETERMINING MUCOPOLYSACCHARIDOSES AND DECISION SUPPORT TOOLOctober 2018October 2023Allow6010YesNo
16085022Compression/Decompression Method and Apparatus for Genomic Variant Call DataSeptember 2018July 2023Allow5821NoNo
16117432Recovering Timing Information from DNA Encoded DataAugust 2018October 2022Allow4920YesNo
16034058AN ADAPTIVE EXPERT SYSTEM FOR ANALYSIS AND CLASSIFICATION OF DNA SAMPLE DATAJuly 2018June 2023Allow5931YesNo
16030296COMPUTER-AIDED DIAGNOSTIC SYSTEM FOR EARLY DIAGNOSIS OF PROSTATE CANCERJuly 2018July 2022Allow4810NoNo
16028241METHOD TO SCREEN HIGH AFFINITY ANTIBODYJuly 2018October 2022Allow5111NoNo
16011753Systems and Methods for the Interpretation of Genetic and Genomic Variants via an Integrated Computational and Experimental Deep Mutational Learning FrameworkJune 2018April 2023Abandon5811NoNo
16062075A NATURAL PRODUCT AND GENETIC DATA ANALYSIS AND DISCOVERY SYSTEM, METHOD AND COMPUTATIONAL PLATFORM THEREFORJune 2018July 2023Allow6021YesNo
15987713VISUALIZATION, COMPARATIVE ANALYSIS, AND AUTOMATED DIFFERENCE DETECTION FOR LARGE MULTI-PARAMETER DATA SETSMay 2018October 2022Allow5321YesNo
15987541SAMPLE ANALYSIS WITH TEST DETERMINATION BASED ON IDENTIFIED CONDITIONMay 2018August 2022Allow5121YesNo
15777316Method For Calibrating A Data Set Of A Target Analyte Using A Normalization CoefficientMay 2018October 2023Allow6021YesNo
15773602METHOD AND DEVICE FOR MODELLING HUMAN OR ANIMAL TISSUEMay 2018April 2023Abandon5911NoNo
15902855Nucleic Acid Based Data Storage Using Enzymatic BioencryptionFebruary 2018November 2022Allow5731YesNo
15932273Method of Treatment of Disease and Method for Quantifying the Level of Minimal Residual Disease in a SubjectFebruary 2018January 2023Allow5931YesNo
15865166SYSTEMS AND METHODS FOR CHARACTERIZING EXTRACELLULAR VESICLE (EV) POPULATION BY PREDICTING WHETHER THE EV ORIGINATES FROM B, T, OR DENDRITIC CELLSJanuary 2018February 2023Allow6011YesNo
15848602HEART RATE PATH OPTIMIZERDecember 2017December 2023Allow6051YesNo
15847569SYSTEM, METHOD, AND ARTICLE FOR DETECTING ABNORMAL CELLS USING MULTI-DIMENSIONAL ANALYSISDecember 2017March 2024Allow6051YesNo
15828540SYSTEM AND METHOD FOR PHYSIOLOGICAL MONITORING AND FEATURE SET OPTIMIZATION FOR CLASSIFICATION OF PHYSIOLOGICAL SIGNALDecember 2017January 2023Allow6031NoNo
15806174METHODS FOR CELL LABEL CLASSIFICATIONNovember 2017December 2021Allow4931NoNo
15571023A CLINICAL PARAMETER CALCULATION-SIMULATION-MONITORING SYSTEMOctober 2017June 2023Abandon6011YesNo
15728614RECONSTRUCTION AND SIMULATION OF NEOCORTICAL MICROCIRCUITRYOctober 2017August 2023Allow6061NoNo
15722978METHOD, STORAGE MEDIUM AND ELECTRICAL DEVICE FOR OBTAINING CYCLE OF PHYSIOLOGICAL SIGNALOctober 2017December 2022Allow6051YesNo
15700988Apparatus and method for determining chemical inputSeptember 2017September 2022Allow6041NoNo
15661942COPY NUMBER ALTERATION AND REFERENCE GENOME MAPPINGJuly 2017July 2022Allow5940YesNo
15639724METHOD AND DEVICE FOR ASSESSING FEASIBILITY OF BIOCHEMICAL REACTION IN ORGANISMJune 2017March 2023Allow6031YesNo
15536307METHOD FOR DETERMINING THE FIBRINOGEN CONCENTRATION IN A BIOLOGICAL SAMPLEJune 2017October 2022Allow6051YesNo
15394138METHODS AND SYSTEMS TO TREAT AN INFECTION FROM PHENAZINE CONTAINING BACTERIA AND RELATED COMPOUNDS AND COMPOSITIONSDecember 2016March 2023Allow6071YesNo
15285935A METHOD OF FORMULATING A MULTICOMPONENT DRUG USING BASES EVALUATED BY MAHALANOBIS TAGUCHI METHODOctober 2016October 2022Allow6071YesNo
15257019NEURAL OSCILLATION MONITORING SYSTEMSeptember 2016September 2023Allow6071NoNo
15102209OLIGONUCLEOTIDE DATA STORAGE ON SOLID SUPPORTSJune 2016October 2023Allow6081NoNo
15036951METHODS FOR ASSESSING CELL VIABILITY OR PREDICTING CELL RESPONSE TO A TREATMENT USING CELL MOVEMENTMay 2016September 2022Allow6071YesNo
14326810DETERMINING A RECOVERY INDICATOR USING HEART RATE DATAJuly 2014June 2022Allow6071YesNo
12949420REAGENT KITS FOR DIAGNOSIS OF HEPATOCARCINOMANovember 2010June 2022Allow6071YesYes
11973583Method and system for determining the reliability of forensic interpretationOctober 2007March 2020Abandon60120YesYes

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner VANNI, GEORGE STEVEN.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
1
Examiner Affirmed
1
(100.0%)
Examiner Reversed
0
(0.0%)
Reversal Percentile
1.3%
Lower than average

What This Means

With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.

Strategic Value of Filing an Appeal

Total Appeal Filings
8
Allowed After Appeal Filing
0
(0.0%)
Not Allowed After Appeal Filing
8
(100.0%)
Filing Benefit Percentile
0.8%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner VANNI, GEORGE STEVEN - Prosecution Strategy Guide

Executive Summary

Examiner VANNI, GEORGE STEVEN works in Art Unit 1672 and has examined 84 patent applications in our dataset. With an allowance rate of 83.3%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 51 months.

Allowance Patterns

Examiner VANNI, GEORGE STEVEN's allowance rate of 83.3% places them in the 58% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.

Office Action Patterns

On average, applications examined by VANNI, GEORGE STEVEN receive 2.58 office actions before reaching final disposition. This places the examiner in the 72% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by VANNI, GEORGE STEVEN is 51 months. This places the examiner in the 6% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +19.1% benefit to allowance rate for applications examined by VANNI, GEORGE STEVEN. This interview benefit is in the 61% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 29.0% of applications are subsequently allowed. This success rate is in the 57% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 40.0% of cases where such amendments are filed. This entry rate is in the 62% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 66.7% of appeals filed. This is in the 47% percentile among all examiners. Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.

Petition Practice

When applicants file petitions regarding this examiner's actions, 59.3% are granted (fully or in part). This grant rate is in the 60% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 3% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 2.9% of allowed cases (in the 75% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.